Articles tagged with Multiple Sclerosis
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
Researchers analyzed blood samples from 114 patients with MS and 21 healthy participants to track immune changes before relapse. They found increased EBV lytic activity in immune cells up to three months before MS relapse and discovered elevated expression of genes linked to MS risk.
A study of 509 people with MS found that B-cell–depleting therapies were associated with lower relapse rates and reduced MRI lesion volume, but no differences in disability scores after two years. The study suggests that doctors should consider patient characteristics when selecting therapy.
A new study reveals striking biological similarities between five major illnesses, including long Covid and PTSD, suggesting common underlying mechanisms. Chronic fatigue syndrome, rheumatoid arthritis, and multiple sclerosis may be driven by shared regulatory networks in immune and metabolic systems.
A new drug patch is being developed to promote the repair of damaged myelin sheaths in multiple sclerosis patients. The patch, which delivers a low dose of theophylline, is being tested in a Phase I clinical trial for its safety and tolerability.
A new MS therapy uses peptide-coupled red blood cells to redirect the immune response, potentially stopping the disease without suppressing the immune system. The clinical trial shows promising results, with the therapy showing good tolerability and safety.
A study by the University of Eastern Finland found that walking performance and daily physical activity are strongly associated with quality of life in people with multiple sclerosis. Lower disability levels and better walking performance were linked to better perceived quality of life.
A large population-based study found that emergency diagnoses are common across multiple conditions, including Parkinson’s disease and coronary heart disease, and are consistently associated with worse outcomes. The study suggests that emergency diagnosis is a common phenomenon across diverse diseases and is linked to higher mortality ...
A randomized controlled trial on levidex, a digital health application, has shown clinically significant improvement in disease-specific quality of life for people with multiple sclerosis. The study found that levidex improved MS-specific quality of life, depressive symptoms, and social functioning in participants.
A study published in Neurology Open Access found that Black people with multiple sclerosis (MS) die from the disease at a younger age than white people. The study also found an increasing trend of deaths related to high blood pressure among both groups, emphasizing the need for targeted interventions to control this risk factor.
Researchers have found that B-cell depletion therapies exert their beneficial effect by mobilizing regulatory immune cells from the gut, which help regulate immune responses and may have a positive impact on MS course. The study suggests new possibilities for developing future therapies that harness beneficial gut immune cells.
A large national study found that multiple sclerosis (MS) death rates vary significantly by age, geography, and race. The analysis, led by the Keck School of Medicine of USC, also found that co-occurring conditions, including high blood pressure and cardiac arrest, were linked to increased mortality among people with MS.
A novel salvage surgical approach combining internal neurolysis and targeted glycerol injection has provided durable pain relief for a patient with severe, treatment-resistant MS-TN. The procedure was successful in preserving sensation and reducing medication use.
Researchers discovered that damaged myelin generates abnormal rhythms in the sleeping brain, linked to disruptions in brain circuit stability. This finding may help design non-invasive approaches to repair myelin during sleep, improving sleep quality in patients with MS and Alzheimer's disease.
A systematic review and meta-analysis found two air pollutants associated with an increased risk of Parkinson's disease. The study suggests that long-term exposure to fine particulate matter (PM2.5) may interact with genetic susceptibility, leading to oxidative stress and neuroinflammation.
A new study describes a gene therapy strategy that uses the brain's glymphatic transport system to distribute engineered viral vectors throughout the brain. This approach enables preferential targeting of human glial cells while minimizing exposure to other cell types and organs, addressing two major challenges in neurological medicine.
A Norwegian Swedish clinical trial found that rituximab is comparable to ocrelizumab in newly diagnosed relapsing multiple sclerosis, offering a more affordable treatment option. The study's findings have major implications for healthcare sustainability and global treatment access.
A study analyzing 287 people with MS found distinct patterns of brain damage and repair linked to disease severity. Genetic variants contributing to MS were associated with inflammation, immune cell activity, and myelin repair.
A new study finds that multiple sclerosis has a substantial impact on social life and work, with 51% of people reporting an effect. The study highlights the need for comprehensive care addressing not only physical health but also daily functioning, employment, and overall wellbeing.
Lili Yang and her team aim to develop a universal CAR-NKT cell immunotherapy for multiple sclerosis, providing a sustained therapeutic effect that daily or weekly medications cannot match. The approach targets the core biological mechanisms of MS, offering a potentially more significant delay or even cure.
Research finds different underlying factors driving growth in people living with Parkinson's disease, multiple sclerosis, and motor neuron disease. Improvements in treatment and care contribute to increased life expectancy for MS and MND patients.
A study analyzing French and Swedish national health databases reveals a rise in Parkinson's disease, multiple sclerosis, and motor neuron diseases' prevalence worldwide. Improved life expectancy and therapies contribute to the increase in multiple sclerosis cases, while population aging is the primary driver of ALS rising incidence.
A blood test can identify signs of Alzheimer's Disease decades before symptoms appear, suggesting early detection and potential treatment. A new brain imaging test also detects Alzheimer's Disease biomarkers earlier than the current standard, improving diagnosis and treatment options.
A new study has identified a group of blood proteins that can flag multiple sclerosis risk years before diagnosis. Researchers found that these proteins are altered in people who develop MS, potentially leading to early intervention and prevention.
A new study reveals that foamy microglia, overloaded with fat droplets, are associated with rapid disease progression in multiple sclerosis. The findings suggest a more complex process than previously thought, involving the absorption of damaged myelin, inflammation, and chronic inflammatory responses.
A new study found irisin reduces clinical symptoms and neuron loss in a mouse model of MS. Irisin also protects neurons from inflammation-driven neurodegeneration.
Researchers compared two prevalent MS models to identify specific scenarios where one model is better suited for studying myelin loss and regeneration. The study analyzed preclinical models alongside human MS tissue samples, revealing genetic changes and insights into disease progression.
The International Progressive MS Alliance has launched the MS Clinical and Imaging Data Resource (MS CIDR) to accelerate understanding of MS progression. The resource contains anonymized data from 14 pharmaceutical industry clinical trials, including MRI scans and clinical visits data from over 13,000 people with progressive MS.
A doctoral thesis reveals two drug molecules that can initiate the regrowth of a protective layer surrounding neurons, enhancing remyelination and accelerating brain tissue repair. The study also identifies scar tissue as a physical barrier to neural regeneration and demonstrates effective treatment with a second drug molecule.
Researchers at CUNY ASRC have uncovered a metabolic switch that influences the formation of myelinating cells, helping shape brain development. The study reveals that glucose levels act as a signal directing behavior during development and can be harnessed to protect myelin in the developing brain and promote repair in disease states.
Researchers discovered that small lesions in white matter can trigger a response in connected grey matter, leading to neuronal activity fall, microglia activation, and synapse loss. However, this response is part of the repair process, essential for brain regeneration.
A multi-institutional team has discovered a novel immune regulatory mechanism mediated by antibodies that selectively shut down overactive immune responses. The 'immune-induced TCR-like antibody' (iTab) can reduce disease severity and delay its onset in a mouse model of autoimmune disease.
NYU Langone Health experts present platform talks on practical strategies to counter medical misinformation, phase 3 X-TOLE2 trial results for novel epilepsy treatment, and exploring healthcare accessibility for patients with disabilities. The Department of Neurology features over 80 presentations from faculty members.
The FDA is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab for treating primary progressive multiple sclerosis in women due to concerns over its lack of effectiveness and potential increased risk of breast cancer. The investigation highlights internal FDA warnings about the drug's safety and effectiv...
A team led by Jiefu Li developed a new method to examine proteins lining the inside surface of blood vessels, revealing two proteins and pathways that play a role in opening and closing the blood-brain barrier. This discovery could help scientists understand how the barrier functions and develop better ways to deliver medicines for neu...
A study published in Neurology Open Access found that having infectious mononucleosis caused by the Epstein-Barr virus is associated with an increased risk of developing multiple sclerosis. After adjusting for other factors, researchers found that people with a history of mono were three times more likely to develop MS.
A new model of brain wiring could shorten the path to developing medicines for multiple sclerosis and other degenerative brain diseases. The model, made of a water-filled gel, replicates the physical properties of human axons and has been successfully grown from human cells in the laboratory.
A recent study has revealed that brain tumors use a protein called MIF to reprogram immune cells, such as macrophages and microglia, to drive tumor growth. The researchers have identified a drug, ibudilast, which can block this process, slowing metastasis in animal models and fresh patient samples.
Multiple sclerosis prevalence more than doubled in England's healthcare system over 30 years, while survival rates increased. Lifestyle factors, including tobacco use and socioeconomic deprivation, were significantly associated with mortality.
Multiple sclerosis (MS) has seen a significant increase in prevalence, with standardised prevalence doubling from 107 per 100,000 people in 2000 to 232 per 100,000 in 2020. The study also found that survival rates improved due to advances in treatments and care, but inequalities persist, particularly in deprived areas.
The Robert A. Winn Excellence in Clinical Trials Award Program is expanding its career development award to include neuropsychiatry researcher-physicians. This expansion aims to improve clinical trial enrollment and represent diverse patient populations affected by complex disorders.
Dr. Ludwig Kappos has made enormous contributions to MS research, advancing clinical trial conduct and outcome measures, and leading international collaborations. He will formally receive the award at the American Academy of Neurology Annual Meeting in Chicago on April 19, 2026.
A genetic mutation found in high-altitude animals may help regenerate myelin sheath and repair nerve damage in conditions like MS and cerebral paralysis. The mutation increases production of a metabolite that promotes myelin production and maturation.
A new study reveals that people of South Asian, African, and European ancestry share common genetic risk factors for multiple sclerosis, despite historic lack of representation in research. The study highlights the importance of diverse representation in research to improve understanding of the disease and develop effective treatments.
A study found that people with changes in their activity patterns were more likely to have worsening disability and loss of brain volume than those whose patterns did not change. Wearable sensors measure physical activity, time spent sitting or inactive, and circadian rhythms.
The International Progressive MS Alliance has funded three global studies to address common symptoms of progressive MS, such as fatigue and cognitive impairment. These Well-Being Phase II Efficacy Awards aim to develop innovative approaches for improving well-being in people with progressive MS.
Myelin swellings are precursor lesions in MS, but research reveals they have a dynamic character, growing, shrinking and recovering. The underlying nerve fibre activity plays a key role in their formation.
A global study found that a group of bacteria, CAG-170, consistently appeared in high numbers in the gut microbiomes of healthy individuals. This species has the capacity to produce Vitamin B12 and break down carbohydrates, suggesting it plays a crucial role in maintaining human health.
A new software tool developed by MIT researchers can reliably and finely resolve eight distinct nerve bundles in live diffusion MRI scans, shedding light on neurodegenerative diseases like Parkinson's and Alzheimer's. The BrainStem Bundle Tool (BSBT) reveals distinct patterns of structural changes in patients with these conditions.
Researchers found that certain types of CD8+ killer T cells are more abundant in people with MS and target the EBV virus, indicating the virus may trigger an immune response leading to progressive neurological damage. The study suggests that interfering with EBV could have a significant impact on other autoimmune diseases.
A study published in the Journal of Neurologic Physical Therapy found that backward walking training improved postural stability and gait speed in most participants with multiple sclerosis. The researchers suggest that this therapy may promote neuroplasticity and be a potential new treatment for improving mobility and decreasing falls.
Dr. Manuel A. Friese has been recognized for his groundbreaking work studying the interactions between inflammation and nerve cell death, which drives disease progression in multiple sclerosis (MS). His research aims to identify new therapeutic targets and bring the field closer to stopping disease progression.
New study finds that progenitor cells in the brain continuously produce new myelin-producing oligodendrocytes, despite being inefficient. This process suggests that treatments harnessing their developmental aspects may increase rapid myelin repair for demyelinating diseases like multiple sclerosis.
A Murdoch University review found that people with MS experience difficulties navigating society and feel ashamed about their condition. The study highlights gaps in the ICF framework, which may not capture the full emotional and social burden of living with MS.
A new study from Karolinska Institutet reveals the Epstein-Barr virus can damage the brain and contribute to multiple sclerosis through molecular mimicry. The researchers found that cross-reactive T cells are significantly more common in people with MS, and targeting these cells may lead to new treatments.
Researchers identify a concrete biological mechanism that triggers MS, focusing on B cells and Epstein-Barr virus. This understanding may help guide future strategies to prevent or treat MS.
Research reveals molecular interaction between environmental and genetic risk factors triggers MS. EBV and gene variants HLA-DR15 haplotype play key roles in disease onset.
A University of Toronto-led study has discovered a potential biomarker linked to multiple sclerosis disease progression that could help identify patients most likely to benefit from new drugs. The findings were validated in both mouse models and humans, suggesting a possible surrogate marker for leptomeningeal inflammation.
Research analyzed blood samples from 1,800 individuals in Sweden, finding links between PFAS and PCB exposure and increased odds of multiple sclerosis. The study also highlighted genetic vulnerability and complex interactions between environmental contaminants and hereditary factors.
A randomized controlled trial found that lipoic acid had a small beneficial effect on slowing brain atrophy in people with progressive multiple sclerosis. However, it did not improve walking speed as the primary clinical outcome. The study suggests that lipoic acid may be worth further investigation for its potential benefits.